Mouse monoclonal antibody
- Protein G Purified
- Species Reactivity:
- WB 1:1000IHC 1:10
- Gene Name:
- Molecular Reference:
- ~90 kDa and ~120 kDa
- Cite This Antibody:
- PhosphoSolutions Cat# p205-190, RRID:AB_2492215
The antigen is a phosphopeptide corresponding to amino acid residues surrounding the phospho-Ser190 of human progesterone receptor.
The antibody is prepared by ammonium sulfate precipitation from tissue culture supernatant followed by purification using a Protein G column.
There is accumulating evidence to suggest that progesterone plays an essential role in the regulation of growth and differentiation of mammary glands and thus may play a key role in breast cancer (Edwards, 2005). The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (PR-A and PR-B forms). In most cell contexts, the B form functions as a transcriptional activator, whereas the A form functions as a transcriptional inhibitor of steroid hormones (Attia et al., 2000; Lin et al., 2003). Recently it has been demonstrated that there is differential hormone dependent regulation of the phosphorylation of the A and B forms of the receptor (Clemm et al., 2000) . Treatment of T47D breast cancer cells with progestin agonist increases the phosphorylation of Ser190 and Ser294 with different kinetics. These phosphorylation events may differentially affect the transcriptional activity of the receptor.
• NR3C3 antibody
• Nuclear receptor subfamily 3 group C member 3 antibody
• PGR antibody
• PR antibody
• PRA antibody
• PRB antibody
• PRGR_HUMAN antibody
• Progesterone receptor antibody
• Progestin receptor form A antibody
• Progestin receptor form B antibody
100 µl in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. Adequate amount of material to conduct 10-mini Western Blots.
Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.
Product Specific References
López-Álvarez, V. M., Modol, L., Navarro, X., Cobianchi, S., & Neurodegenerativas, E. (2015). Early increasing-intensity treadmill exercise reduces neuropathic pain by preventing nociceptor collateral sprouting and disruption of chloride cotransporters homeostasis after peripheral nerve injury. Pain. Jun 18. PMID: 26090759
Silayeva L, Deeb TZ, Hines M, Kelley MR, Munoz MB, Lee HHC, Brandon NJ, Dunlop J, Maguire J, Davies PA, Moss SJ. (2015) KCC2 activity is critical in limiting the onset and severity of status epilepticus. PNAS. Mar 2. pii: 201415126. PMID: 25733865
Mòdol, L., Casas, C., Llidó, A., Navarro, X., Pallarès, M., & Darbra, S. (2014). Neonatal allopregnanolone or finasteride administration modifies hippocampal K+ Cl? co-transporter expression during early development in male rats. The Journal of steroid biochemistry and molecular biology, 143, 343-347. PMID: 24861264
Modol, L., Cobianchi, S., & Navarro, X. (2014). Prevention of NKCC1 phosphorylation avoids downregulation of KCC2 in central sensory pathways and reduces neuropathic pain after peripheral nerve injury. PAIN, 155(8), 1577-1590. PMID: 24813295
Mòdol, L., Mancuso, R., Alé, A., Francos-Quijorna, I., & Navarro, X. (2014). Differential effects on KCC2 expression and spasticity of ALS and traumatic injuries to motoneurons. Frontiers in cellular neuroscience, 8:7. PMID: 24478630
Sarkar J, Wakefield S, MacKenzie G, Moss SJ and Maguire J. (2011) Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors. J Neurosci. 31(50):18198-210. PMID: 22171026
Lee HH, Deeb TZ, Walker JA, Davies PA, Moss SJ (2011) NMDA receptor activity downregulates KCC2 resulting in depolarizing GABAA receptor-mediated currents. Nat Neurosci. Jun;14(6):736-43. PMID: 21532577